The evolution of immuno-oncology is so rapid that the research stage is already outdated!

The huge number of developments and the volume of data in immuno-oncology have led to the creation of a partnership between the Faculté de médecine de l’université Paris Descartes and Kephren to foster interaction between key stakeholders, namely clinics and research facilities, during Immunity and Cancer Scientific Days (ICSD).  

Biotech Finances interviewed Eric Tartour, head of Georges Pompidou European Hospital’s head of biological immunity and academic director of the first ICSD, to learn about the current state of drug development and which products are soon to be - or already on - the market.